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Abstract 
Background: Pulmonary pleomorphic carcinoma (PPC) follows an aggressive clinical course and outcomes are 
disappointing. Due to its rarity, however, the clinicopathological and molecular characteristics of this disease remain 
unclear.
Methods: We retrospectively evaluated the efficacy of chemotherapy and molecular targeted therapy in 16 patients 
with PPC who received chemotherapy or EGFR-TKI. We also investigated the status of EGFR mutation, KRAS mutation 
and ALK expression.
Results: On histologic review of the malignant epithelial component, adenocarcinoma was identified in seven cases 
(43.8 %), large cell carcinoma in four (25.0 %), and squamous cell carcinoma in two (12.5 %). For the sarcomatoid 
component, 14 cases (87.5 %) had both spindle cell tumor and giant cell and 2 (12.5 %) had giant cell. Eleven patients 
received cytotoxic chemotherapy as first-line but did not achieve an objective response, although one patient who 
received docetaxel as second-line achieved a partial response. We also found that one patient achieved long stable 
disease of about 9 years without progression after receiving cisplatin and gemcitabine treatment. EGFR mutation, 
KRAS mutation and ALK expression were investigated in 14 patients whose tumor specimens were available. EGFR 
mutation was observed in 2 (14.3 %) and KRAS mutation in 3 (21.4 %), while no patient was positive for ALK expres-
sion. One patient harboring EGFR exon 19 deletion was treated with gefitinib after postoperative recurrence and 
achieved a complete response of about 35 months.
Conclusions: Although advanced PPC showed a poor response to chemotherapy, one patient with EGFR mutation 
achieved an extended complete response. We therefore recommend the evaluation of driver gene alteration such as 
EGFR in the treatment of advanced PPC.
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Background
Pulmonary pleomorphic carcinoma (PPC) is rare, with 
an incidence of 0.1–0.4  % of all non-small lung can-
cers (NSCLC) [1–5]. According to the World Health 
Organization classification report in 2004 [4], pulmo-
nary pleomorphic carcinoma is defined as poorly differ-
entiated adenocarcinoma, squamous cell carcinoma or 
large cell carcinoma, containing a component of spin-
dle or giant cells with a sarcomatoid tumor component 
of at least 10  % [4]. Although clinical outcome is stage-
dependent, it follows a more aggressive clinical course 
and has a worse prognosis than other histological types 
of NSCLC [6–10]. Furthermore, some recent reports 
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have noted that PPC is often refractory to chemotherapy 
regimens which provide active treatment for NSCLC [8–
12]. Due to its rarity, no optimal treatment for PPC has 
yet been established.
In NSCLC, the discovery that somatic alterations of 
driver gene, including epidermal growth factor recep-
tor (EGFR) and anaplastic large kinase (ALK) gene, are 
found in a subset of lung adenocarcinomas and are asso-
ciated with sensitivity to molecular target therapy has 
provided a rationale for the development of therapies in 
NSCLC [13–15]. Several reports noted that EGFR muta-
tions were recognized in 15–20  % of patients with PPC 
but that the response to EGFR tyrosine kinase receptor 
inhibitor (TKI) was weak and transient as a consequence 
of tumor heterogeneity [8, 10, 11, 16–18].
Here, we retrospectively analyzed the efficacy of chem-
otherapy and molecular targeted therapy in patients with 
advanced or metastatic PPC, and characterized their 
somatic alteration status, particularly for EGFR mutation, 
K-ras mutation, and ALK immunohistochemistry (IHC).
Patients and methods
Patient selection
PPC was diagnosed according to the 2004 World Health 
Organization classification [4]. Diagnoses were based on 
light microscopy findings and confirmed by IHC exami-
nation. The histological diagnosis was reviewed by one of 
the authors (K.T.). From January 1998 to April 2010, 65 
patients were histologically diagnosed with PPC by sur-
gical resection, transbronchial lung biopsy, or computed 
tomography (CT) guided needle biopsy at our institution. 
Of these 65, 13 had received chemotherapy and 3 had 
received concurrent chemoradiotherapy, giving a total of 
16 consecutive patients for final enrollment as subjects of 
this study. The protocol was approved by the institutional 
review board of National Cancer Centre Hospital and we 
reviewed the medical records of all of these patients.
EGFR mutation, KRAS mutation, and ALK‑IHC analysis
Activating EGFR mutations (i.e., exon 19 in-frame dele-
tion and exon 21 L858 R missense mutations) and KRAS 
mutation in exon 2 (codon 12 and codon 13) were exam-
ined in paraffin-embedded tumor specimens by high-res-
olution melting assay using LCGreen (Idaho Technology) 
on a LightCycler (Roche Diagnostics), as previously 
described [19]. These PCR products were denatured at 
95 °C for 10 min and cooled to 40 °C to promote the for-
mation of heteroduplexes. The LightCycler capillary was 
transferred to an HR-1 (Idaho Technology), an high-res-
olution melting assay instrument, and heated at a tran-
sition rate of 0.3  °C/s. Data were acquired and analyzed 
using the accompanying software (Idaho Technology). 
After normalization and temperature-adjustment steps, 
melting curve shapes from 78.5 to 85.5  °C were com-
pared between the tumor samples and control samples. 
Human Genomic DNA (Roche Diagnostics) was used as 
the negative control sample with wild-type EGFR. Sam-
ples revealing skewed or left-shifted curves as compared 
with the control samples were judged to have mutations 
without positive controls.
ALK gene fusions were analyzed by immunohisto-
chemistry. Four-micrometer-thick sections were depar-
affinized. Heat-induced epitope retrieval was performed 
with targeted retrieval solution (pH 9) (Dako, Carpinte-
ria, CA). The slides were then incubated with primary 
antibodies against ALK protein (1:40, 5A4; Abcam, Cam-
bridge, UK) for 30  min at room temperature. Immuno-
reactions were detected using the EnVision-FLEX and 
LINKER (Dako). The reactions were visualized with 
3,3′-diaminobenzidine, followed by counterstaining with 
hematoxylin.
To evaluate the genetic heterogeneity of PPC, we also 
investigated EGFR IHC in two different histological 
types. For immunohistochemical staining, formalin-fixed, 
paraffin-embedded tissues were cut into 4-μm-thick sec-
tions and deparaffinized, then subject to heat-induced 
epitope retrieval with Target Retrieval Solution (Dako, 
Carpinteria, CA, USA). The primary antibody used was 
a rabbit monoclonal antibody against human EGFR with 
the DEL (E746-A750del) mutation (1:100, clone 6B6, Cell 
Signaling Technology, Danvers, MA, USA) and a rab-
bit monoclonal antibody against human EGFR with the 
L858R mutation (1:200, clone 43B2, Cell Signaling Tech-
nology) [20]. Antibodies were diluted in SignalStain (Cell 
Signaling Technology) and the slides were incubated 
with each primary antibody for 1 h at room temperature. 
Immunoreactions were detected using the EnVision Plus 
system (Dako) and 3, 3′-diaminobenzidine, followed by 
counterstaining with hematoxylin.
Assessment and analysis
Clinical information was obtained from medical records. 
Clinical disease staging was reassessed according to the 
latest International Union Against Cancer staging cri-
teria [21]. Response to chemotherapy and survival were 
assessed retrospectively and classified according to the 
Response Evaluation Criteria for Solid Tumors, version 
1.1 [22]. Progression-free survival (PFS) was defined as 
the time from the first day of chemotherapy to detec-
tion of the earliest signs of disease progression or death 
from any cause. Overall survival (OS) was defined as 
the time from the first day of chemotherapy to the last 
day on which the patient was confirmed to be alive 
or dead from any cause. Survival was estimated using 
the Kaplan–Meier method. Fisher’s exact and χ2 test 
was used to examine the association of two categorical 
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variables. Differences with probability values of <0.05 
were considered statistically significant. STATA version 




Clinical characteristics of the 16 patients who were finally 
enrolled are listed in Table  1. Median age was 61  years 
(range 43–77  years). Ten patients (62.5  %) were male 
and six (37.5  %) were female. Twelve patients (75.0  %) 
were ex-smokers and their median pack-years was 45.5 
(range 17–124). Ten patients (62.5 %) had relapsed after 
curative surgery, four (25.0  %) were initially diagnosed 
with advanced disease at stage IV, and two (12.5 %) were 
diagnosed with locally advanced disease at stage IIIA. 
Among the relapsed patients who had undergone cura-
tive surgery, none had received adjuvant chemotherapy. 
Two patients with stage IIIA disease and one who had 
relapse of mediastinal and supraclavicular lymph node 
metastases received concurrent chemoradiotherapy. 
Thirteen patients (81.3  %) received systemic chemo-
therapy, including cytotoxic agents or molecular targeted 
agents. Ten patients were diagnosed by the resected pri-
mary tumor; of the other six, three were diagnosed by CT 
guided needle biopsy and three by autopsy.
Pathological features
On histologic review of the malignant epithelial component, 
adenocarcinoma was identified in seven cases (43.8 %), large 
cell carcinoma in four (25.0  %), squamous cell carcinoma 
in two (12.5  %), NSCLC in two (12.5  %), and adenosqua-
mous carcinoma in one (6.3 %). For the sarcomatoid com-
ponent, two cases (12.5 %) had giant cell tumors. Of the 14 
cases (87.5 %) who had both spindle cell tumors and giant 
cell tumors, the spindle cell tumor was dominant in nine 
(56.3 %) while the giant cell was dominant in five (31.3 %).
Molecular profile
EGFR mutation, KRAS mutation and ALK-IHC were 
investigated in the 14 patients whose tumor specimens 
were available (Table 2). EGFR mutation was observed in 
2 (14.3 %) of these 14 patients. The histological features of 
the patient harboring EGFR exon 19 deletion was adenos-
quamous carcinoma with spindle cell and giant cell tumor 
and that of the patient harboring EGFR L858R mutation 
in exon 21 was large cell carcinoma with spindle cell and 
giant cell tumor. KRAS mutation was observed in three 
patients (21.4 %). Two patients with EGFR mutation were 
never smoker, while all patients with KRAS mutation were 
ex-smokers. No patient was positive for ALK-IHC.
Next, regarding the two cases harboring EGFR muta-
tion, we evaluated the mutated EGFR protein expression 
using a mutation-specific antibody against EGFR muta-
tions in both the epithelial and sarcomatoid components. 
In patient No. 2, we found that IHCs by mutation-spe-
cific antibody were positive in adenocarcinoma (Fig. 1a), 
squamous cell carcinoma (Fig.  1b), and sarcomatoid 
components (Fig.  1c). And patient No. 15 progressed 
after concurrent chemoradiotherapy and so we could not 
check the mutated EGFR protein expression in both the 
epithelial and sarcomatoid components.
Treatment and efficacy
Of the 13 patients with advanced stage disease, 11 
patients received cytotoxic chemotherapy as first-
line chemotherapy. Among them, however, no patient 
Table 1 Patient characteristics
CT-NB CT-guided needle biopsy, NOS not otherwise specified
a Ex-smoker (n = 12)
Characteristic Number of patients (n = 16)
Sex
 Male 10 (62.5 %)
 Female 6 (37.5 %)
Age (years)
 Median (range) 61 (43–77)
ECOG-PS
 0 3 (18.8 %)
 1 10 (62.5 %)
 2 3 (18.8 %)
Smoking status
 Never smoker 4 (25.0 %)
 Ex-smoker 12 (75.0 %)
Pack-yearsa
 Median (range) 45.5 (17–124)
Clinical stage
 IIIA 2 (12.5 %)
 IV 4 (25.0 %)
 Recurrence 10 (62.5 %)
Diagnostic procedure
 Surgery 10 (62.5 %)
 CT-NB 3 (18.8 %)
 Autopsy 3 (18.8 %)
Pathological features
 Epithelial component
  Adenocarcinoma 7 (43.8 %)
  Squamous cell carcinoma 2 (12.5 %)
  Adenosquamous carcinoma 1 (6.3 %)
  Large cell carcinoma 4 (25.0 %)
  NOS 2 (12.5 %)
 Sarcomatoid component
  Spindle cell 0 (0.0 %)
  Giant cell 2 (12.5 %)
  Spindle cell and giant cell 14 (62.5 %)
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achieved an objective response, except one patient (No. 6) 
who received docetaxel as second-line chemotherapy and 
achieved a partial response. In all patients, median PFS for 
first-line chemotherapy was 1.5 (95 % CI 0.6–2.5) months 
and OS was 7.2 (95 % CI 1.4–10.3) months (Table 3). We 
also identified one patient (No. 13) who achieved stable 
disease of about 9  years’ duration without progression 
after undergoing small intestinal resection for ileus due 
to a postoperative recurrence lesion in the small intestine 
and then receiving four cycles of cisplatin and gemcit-
abine treatment for hilar lymph node and bone metasta-
ses. One patient (No. 2) harboring EGFR exon 19 deletion 
was treated with gefitinib after postoperative recurrence 
of mediastinal lymph node and achieved a complete 
response of about 35 months (Fig. 2). Two months after 
she declined further treatment with gefitinib because 
of hemoptysis, she developed progressive disease in a 
mediastinal lymph node and thoracic spine metastases. 
All three patients who received concurrent chemoradio-
therapy with cisplatin plus vinorelbine achieved a par-
tial response (Table  3). Although two patients had early 
recurrence, the third is alive without progression more 
than 5  years after completing chemoradiotherapy. One 
patient (No. 15) harboring EGFR exon 21 point mutation 
developed multiple brain metastases and carcinomatous 
meningitis immediately after chemoradiotherapy and was 
then treated with best supportive care without EGFR-TKI 
because of poor general condition.
Discussion
Previous retrospective studies and case reports suggested 
that PPC is often refractory to the chemotherapy regi-
mens used in active treatment for NSCLC [8–11]. This 
retrospective study also found that PPC is an aggressive 
tumor associated with high cell proliferation and that pal-
liative chemotherapy is associated with a poor response 
in advanced PPC, with a few notable exceptions.
With regard to chemoradiotherapy for locally advanced 
PPC, all three patients achieved a partial response in 
our study. Although two patients had early recurrence, 
the third is alive without progression more than 5 years 
after completing chemoradiotherapy. Some reports 
revealed that PPC treated with chemoradiotherapy 
achieved an objective response without recurrence [10, 
11]. These results if confirmed suggest that chemoradio-
therapy commonly used for NSCLC should be adminis-
tered in unresectable stage III disease with pleomorphic 
carcinoma.
Several recent reports have described cases of PPC 
that responded to cytotoxic chemotherapy contain-
ing platinum and gemcitabine [8–12, 23]. Tamiya et  al. 
mentioned that high expression of human equilibrative 
nucleoside transporter 1 (hENT1), the major transporter 
of gemcitabine, might be associated with high sensitiv-
ity to gemcitabine in PPC [12]. We also experienced one 
patient who achieved long-term stable disease without 
progression after receiving cisplatin and gemcitabine 
Table 2 Association between pathological findings and molecular profile
IHC immunohistochemistry, NOS not otherwise specified, Adeno adenocarcinoma, Squamous squamous cell carcinoma, Large large cell carcinoma, Adenosquamous 
adenosquamous carcinoma













1 M Surgery 2100 Wild Mutated Negative Adeno Giant cell > Spindle cell
2 F Surgery 0 Exon 19 del Wild Negative Adenosquamous Spindle cell > Giant cell
3 M Surgery 1200 Wild Wild Negative Adeno Spindle cell > Giant cell
4 F Surgery 0 Wild Wild Negative Adeno Spindle cell > Giant cell
5 M Surgery 400 Wild Wild Negative Adeno Spindle cell > Giant cell
6 M Surgery 1800 Wild Wild Negative Squamous Spindle cell > Giant cell
7 F Surgery 600 Wild Wild Negative Adeno Spindle cell > Giant cell
8 F Surgery 345 Wild Mutated Negative Large Giant cell > Spindle cell
9 M Autopsy 495 NA NA NA NOS Giant cell > Spindle cell
10 M Biopsy 2480 Wild Wild Negative NOS Giant cell
11 M Autopsy 480 Wild Wild Negative Adeno Giant cell
12 M Biopsy 1600 Wild Mutated Negative Squamous Spindle cell > Giant cell
13 M Surgery 660 Wild Wild Negative Large Giant cell > Spindle cell
14 M Autopsy 1160 Wild Wild Negative Adeno Giant cell > Spindle cell
15 F Surgery 0 Exon 21 L858R Wild Negative Large Spindle cell > Giant cell
16 F Biopsy 0 NA NA NA Large Spindle cell > Giant cell
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treatment. We propose that cisplatin and gemcitabine 
treatment may be an active chemotherapy for PPC.
In this study, we also investigated EGFR mutation, 
KRAS mutation and ALK-IHC in the 14 patients with 
PPC whose tumor specimens were available. We found 
that two (14.3  %) of these patients harbored EGFR 
mutation. One patient treated with gefitinib achieved a 
complete response, which was moreover sustained for 
about 35  months. Previous reports suggested that the 
incidence of EGFR mutation was about 15–20  % and 
that the response to gefitinib was weak and transient [8, 
10, 11, 16–18]. Kaira et  al. independently investigated 
EGFR mutations in both the adenocarcinomatous and 
sarcomatoid components of three patients with EGFR 
mutation and detected EGFR mutations in the adeno-
carcinomatous component but not in the sarcomatoid 
component in all cases. Ushiki et  al. revealed a case of 
PPC whose adenocarcinoma cells had an exon 19 dele-
tion and whose sarcomatous cells had both the deletion 
19 and 20 T790 M EGFR mutations [16]. In our present 
study, we could not clearly separate epithelial tumor cells 
from sarcomatoid tumor cells because tumor tissue con-
sisted of a mixture of both components. We then inves-
tigated IHC by mutated EGFR-specific antibody in the 
two different histological types to evaluate the genetic 
heterogeneity of PPC. We found that mutated EGFR 
protein expression was positive in both components. 
We consider that our results are unlikely to be false 
positives, because mutation-specific antibodies against 
EGFR mutation have high specificity in spite of low sen-
sitivity [20]. Tumorigenesis in lung cancer is known to be 
a multistage process by which monoclonal cancer cells 
gradually become heterogeneous owing to clonal evolu-
tion and genetic/epigenetic instability [24–27]. Applying 
computational analysis to the deep sequencing data of 
NSCLC samples, Govindan et  al. suggested that EGFR 
mutation might be acquired at the very initial phase of 
tumorigenesis [28]. We consider that the difference in 
the EGFR mutational heterogeneity of PPC between 
the epithelial and sarcomatoid components represents 
the point at which clonal evolution occurred. Addition-
ally, our results also suggest that driver gene alteration 
such as EGFR should be investigated in the treatment of 
advanced PPC.
One limitation of our study is that the sample size was 
small, due to the rarity of this condition. Additionally, 
10 of 16 patients diagnosed from the resected primary 
tumor did not undergone rebiopsy at the start of chemo-
therapy. For this reason, we did not attempt to identify 
which component of PPC relapsed.
Fig. 1 Two representative cases harboring EGFR mutation by muta-
tion-specific antibody against EGFR mutations in both epithelial and 
sarcomatoid components. a adenocarcinoma component in patient 
No. 2, ×20; b squamous cell carcinoma component in patient No. 2, 
×20; c sarcomatoid component in patient No. 2, ×20; d sarcomatoid 
component in patient No. 15, ×20
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Conclusions
All the patients who received concurrent chemora-
diotherapy achieved at least a partial response and 
if confirmed, chemoradiotherapy should be consid-
ered an effective modality in locally advanced dis-
ease. Although this study demonstrated that advanced 
PPC responds poorly to chemotherapy, further clini-
cal trials are needed to investigate the role of pal-
liative chemotherapy for PPC, including platinum 
and gemcitabine treatment. Additionally, one patient 
with EGFR mutation achieved a long-term complete 
response. We therefore recommend evaluating driver 
gene alteration, such as EGFR, in the treatment of 
advanced PPC.
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